Abstract:Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy that presents with highly heterogenous clinical syndromes. We perform cross-sectional data-driven discovery of independent patterns of brain atrophy and hypometabolism across the entire PSP spectrum. We then use these patterns to predict specific clinical features and to assess their relationship to phenotypic heterogeneity. We included 111 patients with PSP (60 with Richardson syndrome and 51 with cortical and subcortical variant subtypes). Ninety-one were used as the training set and 20 as a test set. The presence and severity of granular clinical variables such as postural instability, parkinsonism, apraxia and supranuclear gaze palsy were noted. Domains of akinesia, ocular motor impairment, postural instability and cognitive dysfunction as defined by the Movement Disorders Society criteria for PSP were also recorded. Non-negative matrix factorization was used on cross-sectional MRI and fluorodeoxyglucose-positron emission tomography (FDG-PET) scans. Independent models for each as well as a combined model for MRI and FDG-PET were developed and used to predict the granular clinical variables. Both MRI and FDG-PET were better at predicting presence of a symptom than severity, suggesting identification of disease state may be more robust than disease stage. FDG-PET predicted predominantly cortical abnormalities better than MRI such as ideomotor apraxia, apraxia of speech and frontal dysexecutive syndrome. MRI demonstrated prediction of cortical and more so sub-cortical abnormalities, such as parkinsonism. Distinct neuroanatomical foci were predictive in MRI- and FDG-PET-based models. For example, vertical gaze palsy was predicted by midbrain atrophy on MRI, but frontal eye field hypometabolism on FDG-PET. Findings also differed by scale or instrument used. For example, prediction of ocular motor abnormalities using the PSP Saccadic Impairment Scale was stronger than with the Movement Disorders Society Diagnostic criteria for PSP oculomotor impairment designation. Combination of MRI and FDG-PET demonstrated enhanced detection of parkinsonism and frontal syndrome presence and apraxia, cognitive impairment and bradykinesia severity. Both MRI and FDG-PET patterns were able to predict some measures in the test set; however, prediction of global cognition measured by Montreal Cognitive Assessment was the strongest. MRI predictions generalized more robustly to the test set. PSP leads to neurodegeneration in motor, cognitive and ocular motor networks at cortical and subcortical foci, leading to diverse yet overlapping clinical syndromes. To advance understanding of phenotypic heterogeneity in PSP, it is essential to consider data-driven approaches to clinical neuroimaging analyses.

Transcriptional expression patterns of the cortical morphometric similarity network in progressive supranuclear palsy

Aberrant dynamic functional network connectivity in progressive supranuclear palsy

Abnormal Structural–Functional Coupling and MRI Alterations of Brain Network Topology in Progressive Supranuclear Palsy

Morphometric similarity differences in drug‐naive Parkinson's disease correlate with transcriptomic signatures

Abnormal structural‒functional coupling patterning in progressive supranuclear palsy is associated with diverse gradients and histological features

P2‐025: Genetic and Epigenetic Influences on Brain Gene Expression in Psp

Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies

Cortical Structural Changes of Morphometric Similarity Network in Early-Onset Schizophrenia Correlate with Specific Transcriptional Expression Patterns

Reproducible Network and Regional Topographies of Abnormal Glucose Metabolism Associated with Progressive Supranuclear Palsy: Multivariate and Univariate Analyses in American and Chinese Patient Cohorts.

Longitudinal Macro/Microstructural Alterations of Different Callosal Subsections in Parkinson’s Disease Using Connectivity-Based Parcellation

Morphometric Similarity Network Alterations in COVID-19 Survivors Correlate with Behavioral Features and Transcriptional Signatures

MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy

Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease

Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes

Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum

Single-cell transcriptomic and neuropathologic analysis reveals dysregulation of the integrated stress response in progressive supranuclear palsy

Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndrome

Brain Gray Matter Abnormalities in Progressive Supranuclear Palsy Revisited.

Clinical Features of Progressive Supranuclear Palsy.

Voxelwise meta-analysis of white matter abnormalities in progressive supranuclear palsy

CSF Proteomics in Patients With Progressive Supranuclear Palsy